August 15, 2024 02:11 PM EDTUpdated 03:45 PM
People
FDA+

Up­dat­ed: Lykos cut­ting most of staff less than a week af­ter FDA re­jec­tion

Max Bayer

Pharma Reporter

Lykos Ther­a­peu­tics is cut­ting 75% of its staff fol­low­ing the FDA’s re­jec­tion last week of its MD­MA-as­sist­ed ther­a­py, the com­pa­ny said Thurs­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Mer­ck and Dai­ichi’s re­ject­ed HER3 ADC clears a Phase 3 in cer­tain lung can­cers

Nu­ra Bio rais­es $68M for clin­i­cal tests of SARM1 in­hibitor to po­ten­tial­ly slow or pre­vent nerve de­gen­er­a­tion

Em­met Stephen­son gives $150M to City of Hope for pan­cre­at­ic can­cer, cre­at­ing mil­lion-dol­lar re­search prize

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times